Unpublished work from our lab (U. Ganguly, personal communication) suggests that AD-relevant tau PTMs can inhibit mitophagy induction via urolithin A and nicotinamide mononucleotide, indicating that mitophagy suppression may be an inherent part of tau pathology that reduces the efficacy of mitophagy stimulators as a treatment for AD. Here, MAPT is linked to Alzheimer disease.